Anzeige
Mehr »
Samstag, 28.06.2025 - Börsentäglich über 12.000 News
Blockbuster-Bohrergebnisse: Gold-Antimon-Fund in Nevada trifft geopolitischen Nerv
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A2PJPB | ISIN: US45166A1025 | Ticker-Symbol: 30J
Stuttgart
27.06.25 | 21:33
18,100 Euro
0,00 % 0,000
1-Jahres-Chart
IDEAYA BIOSCIENCES INC Chart 1 Jahr
5-Tage-Chart
IDEAYA BIOSCIENCES INC 5-Tage-Chart
RealtimeGeldBriefZeit
18,10018,40027.06.
18,20018,30027.06.

Aktuelle News zur IDEAYA BIOSCIENCES Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
FrIDEAYA Biosciences, Inc.: IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)22SOUTH SAN FRANCISCO, Calif., June 27, 2025 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a precision medicine oncology company committed to the discovery...
► Artikel lesen
DoWells Fargo initiates Ideaya Biosciences stock with overweight rating3
DiIdeaya Biosciences-Aktionäre wählen Direktoren und genehmigen Wirtschaftsprüfer bei Jahresversammlung1
DiIDEAYA Biosciences, Inc. - 8-K, Current Report1
30.05.IDEAYA Biosciences, Inc.: IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)150SOUTH SAN FRANCISCO, Calif., May 30, 2025 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a precision medicine oncology company committed to the discovery...
► Artikel lesen
06.05.IDEAYA Biosciences, Inc. - 10-Q, Quarterly Report1
06.05.IDEAYA Biosciences GAAP EPS of -$0.82 misses by $0.151
IDEAYA BIOSCIENCES Aktie jetzt für 0€ handeln
06.05.FDA erteilt IDEAYA Zulassung für Phase-1-Studie eines neuen Krebsmedikaments1
06.05.FDA clears IDEAYA's Phase 1 trial for new cancer drug1
06.05.IDEAYA Biosciences, Inc. Reports First Quarter 2025 Financial Results and Provides Business Update85~$1.05 billion of cash, cash equivalents and marketable securities as of March 31, 2025, and an updated cash runway guidance into 2029; commercial readiness activities...
► Artikel lesen
06.05.IDEAYA Biosciences, Inc. - 8-K, Current Report-
06.05.IDEAYA Biosciences, Inc.: IDEAYA Biosciences Announces US FDA IND-Clearance for IDE849, a Potential First-in-Class DLL3 TOP1 ADC, for a Phase 1 Study in Solid Tumors63Targeting to evaluate IDE849 (SHR-4849) in SCLC, NETs, and other DLL3-upregulated solid tumors, and in combination with IDE161/PARG to potentially enhance durability ...
► Artikel lesen
05.05.Why IDEAYA Biosciences, Inc. (IDYA) is Among the Best Small Cap Stocks to Buy with the Biggest Upside Potential2
26.04.IDEAYA Biosciences Grants Stock Options To New Employees Under 2023 Inducement Plan2
14.04.IDEAYA macht Fortschritte mit Darovasertib in Studie zu Aderhautmelanom2
14.04.IDEAYA advances darovasertib in uveal melanoma trial2
14.04.IDEAYA Biosciences, Inc.: IDEAYA Biosciences Announces Successful FDA Type D Meeting on Phase 3 Registrational Trial Design for Darovasertib as Neoadjuvant Therapy for Primary Uveal Melanoma92Targeting to initiate Phase 3 randomized registrational trial for darovasertib in the neoadjuvant setting in primary UM in H1 2025 Clinical endpoints supportive...
► Artikel lesen
10.04.IDEAYA Biosciences, Inc.: IDEAYA Biosciences Announces Phase 1/2 Expansion for IDE397 and Trodelvy Combination in MTAP-Deletion Urothelial Cancer136Initiated Phase 1/2 study expansion for IDE397, IDEAYA's MAT2A inhibitor, in combination with Trodelvy®, Gilead's Trop-2 directed ADC, in MTAP-deletion urothelial...
► Artikel lesen
02.04.IDEAYA Biosciences, Inc. - 8-K, Current Report3
31.03.IDEAYA Biosciences, Inc.: IDEAYA Biosciences Receives US FDA Breakthrough Therapy Designation for Darovasertib Monotherapy in Neoadjuvant Uveal Melanoma106Designation enables expedited development and priority regulatory review BTD application was supported by updated clinical data from Ph2 neoadjuvant UM trial...
► Artikel lesen
Weiter >>
53 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1